Opendata, web and dolomites

PORTAL SIGNED

Personalized oncology for refractory and relapsed lymphoma using humanized patient derived othotopic xenografts (ImmunePDOX)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PORTAL project word cloud

Explore the words cloud of the PORTAL project. It provides you a very rough idea of what is the project "PORTAL" about.

portal    refractory    worked    biomedical    paradigm    engagement    leader    maturity    acquired    qualitative    therapeutic    lymphoma    proof    sureda    europdx    interventions    ana    service    educational    brazil    besides    oncology    improvement    oswaldo    line    patient    clinical    cancers    models    resistance    board    pharmaceuticals    foundation    head    remained    strategy    villanueva    solid    original    chemotherapy    idibell    group    reintegrated    xenograft    cruz    12    farre    xenopat    position    combined    dr    reflects    bellvitge    overcoming    policy    programmed    training    therapy    initiating    independent    relapsed    ico    off    privileged    director    transfer    2020    supervised    catalan    mechanisms    contributed    always    treatment    preclinical    empiric    gender    priorities    spain    public    innovative    researcher    scientific    she    option    hematology    personalized    orthotopic    hematological    spin    htlv    multidisciplinary    incorporate    alberto    of    fiocruz    career    infection    re    barcelona    lourdes    relevantly    lymphomas    humanized   

Project "PORTAL" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE 

Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908
website: www.idibell.cat

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE ES (L'HOSPITALET DE LLOBREGAT) coordinator 170˙121.00

Map

 Project objective

This proposal is a “PORTAL” to re-incorporate Dr. Lourdes Farre from the Oswaldo Cruz Foundation (FIOCRUZ) in Brazil to Europe at the Catalan Institute of Oncology (ICO), a part of the Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. She will be supervised by Dr. Alberto Villanueva, leader of the Resistance, Chemotherapy and Orthotopic Xenograft Models Group and Director Board of the EuroPDX (www.europdx.eu) in collaboration with Dr. Ana Sureda, Head of the Hematology Department (ICO). Dr. Farre worked at FIOCRUZ for 12 years where she relevantly contributed in lymphoma research and acquired maturity as an independent researcher. Dr. Farre will contribute to ICO/IDIBELL initiating a new research line in resistance in hematological cancers and transfer her knowledge in HTLV-1 infection. She will also contribute to the ICO Hematology Service with a personalized oncology strategy for clinical oncology practice. Knowledge and preclinical models could be transfer to the IDIBELL`s spin-off Xenopat and Pharmaceuticals. She will have access to a solid multidisciplinary training program that will provide qualitative improvement on her career and a privileged position to be reintegrated in a long term research position in Europe. She has always combined scientific activity with educational interventions. Besides scientific dissemination, she programmed public engagement activities. This proposal is a proof-of-concept of personalized oncology for refractory/relapsed lymphoma and aims to study the mechanisms involved in response to therapy using preclinical humanized orthotopic models. Relapsed/refractory lymphomas represent a major treatment challenge and general treatment paradigm has remained empiric. Defining the best therapeutic option for each patient and overcoming such resistance is a priority. Humanized and orthotopic approach is original and innovative. PORTAL reflects the policy priorities of the Europe 2020 strategy and considers gender issues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PORTAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PORTAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

MAREITA (2018)

Mapping Remediation in Italian Literature Beyond the Digital Revolution

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More